Brief Communication
Multiplex ligation-dependent probe amplification (MLPA) analysis is an effective tool for the detection of novel intragenic PLA2G6 mutations: Implications for molecular diagnosis 
Introduction
Autosomal recessive neurodegeneration associated with genetic defects in the PLA2G6 gene [1] may present with a number of phenotypes [2] including presentation in infancy [3, 4] (infantile neuroaxonal dystrophy, INAD, MIM256600), childhood (atypical neuroaxonal dystrophy, neurodegeneration with brain iron accumulation, NBIA MIM610217, Karak syndrome MIM608395) [4, 5] and also in adulthood [6, 7] (early-onset dystonia-parkinsonism MIM612953). Mutation detection rate is particularly high (80-90%) in children with classical clinical and radiological features of infantile PLAN [2, 8] . 1 Classical INAD (infantile onset PLAN) accounts for the majority of cases, and is characterised by infantile onset truncal hypotonia and progressive psychomotor regression [3, 4] . Over time, children develop bulbar dysfunction, pyramidal tract signs, optic atrophy, cerebellar features and extrapyramidal features [3, 4, [9] [10] [11] [12] . MRI features can aid diagnosis [13] [14] [15] . The majority of patients have features of cerebellar atrophy [4] . Cerebellar gliosis is seen in the majority [4] but not all patients have this feature [16] . Some also have evidence of brain iron accumulation [3, 4] . Generalised seizures are often reported [17] [18] [19] . Dysmorphia is rarely described [20] . Death usually occurs around the first decade [3, 4] . Not all patients with typical clinical features of infantile PLAN have mutations in the PLA2G6 gene [4] . Possible explanations for this include genetic heterogeneity [1] , PLA2G6 defects within intronic sequence or regulatory regions and CNVs that are undetected by standard diagnostic mutational screening strategies [21] . In recent years, MLPA has emerged as a high resolution technique to determine relative DNA sequence dosage [22, 23] .
We describe four children with infantile PLAN referred for diagnostic PLA2G6 screening in which both disease-causing mutations were not identified on direct gene sequencing. Further investigation with MLPA analysis detected a novel heterozygous duplication in patient 1 and a novel homozygous deletion in patients 2-4.
Subjects and methods

Patients
The patients described were referred to the West Midlands Regional Genetic Service for PLA2G6 analysis by their local paediatric neurologist/geneticist. The medical case notes were analysed to delineate the clinical features on history and examination. MRI brain scans for patient 1 were reviewed independently by 2 paediatric neuroradiologists (with consensus agreement on disparities).
Molecular genetic investigation
Techniques for DNA/RNA extraction, PLA2G6 sequencing, MLPA analysis and molecular characterisation of the CNVs are outlined in Supplementary data 1.
Results
Clinical cases
Patient 1
Patient 1 was the first child of non-consanguineous healthy Caucasian parents. Early neurodevelopmental milestones were achieved. At 15 months, he developed gait instability and an alternating strabismus. Psychomotor regression ensued and by 19-20 months of age, there was loss of ambulation. Between 2 and 3 years he developed 4-limb spasticity. Speech regression was also evident. He developed severe bulbar dysfunction with excessive drooling and feeding difficulties requiring PEG feeding. Dystonia of all 4-limbs was also evident by age 5 years. He did not have any seizures.
On clinical examination (age 5 years) he was not dysmorphic or microcephalic, but had evidence of a right-sided manifest squint and bilateral horizontal nystagmus. There was excessive drooling and tongue fasciculation. On neurological assessment he was found to have marked axial hypotonia. There was a postural kyphotic curvature of the spine. Limb examination revealed symmetrical 4-limb hypertonicity and hyperreflexia but no contractures. Plantar reflexes were upgoing bilaterally. MRI brain examination was undertaken at age 2 and 2.9 years ( Fig. 1 ). Initial MRI scan showed evidence of a hypoplastic cerebellum and vermis ( Fig. 1A and B) . There was no evidence of optic nerve hypoplasia or white matter abnormalities. On repeat MR neuroimaging at age 2.9 years, there was progressive cerebellar atrophy ( Fig. 1C and D) . Although minimal basal ganglia abnormalities were noted on initial imaging (Fig. 1E) , mild iron accumulation within the basal ganglia was evident on repeat imaging (Fig. 1F) . Electromyographic (EMG) signs of chronic denervation were evident in the upper limbs, lower limbs and bulbar musculature. Nerve conduction studies were normal. On EEG, widespread high amplitude fast activity at 16-22 Hz was seen. Visual evoked potentials (VEP) and electroretinogram (ERG) was normal at age 2 years. Ophthalmological review detected bilateral temporal disc pallor. Histological examination of nerve tissue from a rectal biopsy (age 2 years) was normal.
Patient 2
Patient 2, a 4 year old girl was born to healthy consanguineous (2nd cousin) Irish parents. All early developmental milestones were appropriately achieved. Symptom onset at 9-10 months of age commenced with psychomotor regression. She stopped vocalising, developed complete loss of ambulation and could only sit for brief periods with extensive support. There was no evidence of seizures.
On clinical examination, at age 21 months, she was not dysmorphic or microcephalic. There was evidence of marked axial hypotonia and upper and lower limb spasticity (but no contractures or spinal deformity). She had evidence of nystagmus on clinical examination. Ophthalmological examination did not detect any abnormalities. MRI brain (age 18 months) revealed cerebellar atrophy and a marginally narrow pons but no evidence of basal ganglia abnormalities. Electromyogram abnormalities were similar to patient 1. She did not have any other electrophysiological investigations (VER, ERG, EEG) or a sural/skin biopsy as repeated non-attendance at clinic appointments precluded further neurological investigation.
Patients 3 and 4
Patients 3 and 4, dizygotic male twins were born to healthy consanguineous (1st cousin) parents, of Irish origin. There was no family history of neurological disorders and the family were not known to be related to patient 2's kindred. The twins were born at 33 weeks gestation, but despite their prematurity, the postnatal course was uneventful. Early developmental milestones were appropriately achieved, but concerns were raised at 11 months of age as both children were yet to sit independently. At this stage both children were noted to have strabismus. Psychomotor regression ensued in both children with a gradual but progressive loss of cognitive and motor skills. A rapid decline in motor function was seen in patient 3 subsequent to a febrile viral illness at age 22 months. Following this illness, he developed infantile spasms associated with a hypsarrhythmic EEG pattern. At age 26 months, patient 4 also developed seizures (generalised tonic clonic episodes) with an EEG pattern of high voltage slow background with sharp and slow wave discharges seen independently in each temporal region. Repeat EEG (5 months later) showed mild excess of moderate voltage irregular slow activity with runs of high amplitude irregular delta activity with ill defined sharp components independently over both temporal regions. Both children had ophthalmological assessments showing optic atrophy. Over time, both children developed profound axial hypotonia, pyramidal tract features and bulbar dysfunction. MRI brain (at 24 months of age in both children) revealed moderate cerebellar atrophy, but no cerebellar gliosis or brain iron accumulation. Electrophysiological investigation revealed absent sensory nerve action potentials associated with a myopathic pattern on EMG. No clear binocular pattern of vision was evident on VEP. A sural/skin biopsy was not undertaken in either patient.
Molecular genetic investigation
Direct sequencing of PLA2G6 Patient 1: A heterozygous mutation (c.1674delG; p.Leu560Trpf sX5) was detected in exon 12 ( Supplementary Fig. 1) . A 2nd mutation was not detected.
Patient 2-4: Molecular analysis did not detect any mutations in exons 1-4 and 7-17 of the PLA2G6 gene. Repeated failed attempts to amplify exons 5 and 6 (due to polymerase chain reaction failure, Supplementary Fig. 2 ) raised the possibility of an intragenic homozygous deletion.
MLPA analysis
Patient 1: A heterozygous duplication of exons 4, 5, 6 and 7 was identified ( Supplementary Fig. 3) .
Patient 2-4: A homozygous deletion of exons 5 and 6 was detected in all patients ( Supplementary Fig. 4 ).
Molecular genetic characterisation of the CNVs
Patient 1: Fig. 2A -D. Primers were designed for cDNA amplification of a putative tandem duplication from exon 7 to exon 4. Subsequent sequencing of patient 1 confirmed that the exon 4, 5, 6 and 7 duplication occurred within the PLA2G6 gene leading to a pathogenic truncating mutation (r.426-?_1077-?dup p.Lys360LeufsX22).
Patient 2-4: Fig. 2E -G. PCR primers were designed to amplify the region between intron 4 and intron 6. The PCR amplification products were observed for patients but not in control samples.
The genomic breakpoints were identified (g.40638_47282del6632, p.Leu204_Glu298del95) in intron 4 (between 38 537 112 and 38 537 123 bp) and in intron 6 (between 38 530 480 and 38 530 491 bp). The breakpoints could not be further delineated as there is a 12 bp region with 100% homology common to both intron 4 and intron 6.
Discussion
To date, 75 different genetic alterations of PLA2G6 have been reported in PLAN [1] [2] [3] [4] 6, 8, 12, 17] including missense mutations (68%), insertions (0.75%), deletions (14%), nonsense mutations (14%) and splice site mutations (0.75%). We report the use of MLPA in the detection of previously undetected novel large intragenic PLA2G6 rearrangements in four patients with classical infantile PLAN. Although this only a recently reported diagnostic use of MLPA in PLA2G6 analysis [21] , this diagnostic tool has already been successfully used in a number of other conditions [22, 23] Indeed, MLPA analysis of the SCN1A gene in mutation-negative patients with Dravet's syndrome detected a significant chromosomal rear- rangement rate of 12.5% [24, 25] . From this study, we estimate that CNVs may also account for 12.5% PLA2G6 mutations identified in the UK Diagnostic Screening Service.
MLPA analysis has important diagnostic implications. In patient 1, the heterozygous duplication could not be detected by standard direct gene sequencing. In patient 2, failed attempts to amplify exons 5 and 6 could have been due to a number of reasons (failed PCR amplification or the presence of rare SNP variants in primer binding regions). However MLPA alone cannot provide an insight as to the precise genomic location and/or potential functional outcomes of the deletion/duplication [26] . Subsequent molecular characterisation has provided important information regarding the nature of these CNVs. In case 1, analysis of cDNA revealed expression of mutant mRNA species containing a tandem duplication of exon 4, 5, 6, and 7, resulting in a frameshift and premature stop codon. In case 2, genomic delineation of the centromeric and telomeric breakpoints revealed that both breakpoints were within an AluY repeat sequence (http://www.repeatmasker.org/) in intron 4 and intron 6 (showing 94% overall homology) (www.blast.ncbi.nlm.nih.gov). An Alu recombination-mediated deletion (ARMD) as a result of misalignment of the Alu Y repeats is thus the most likely mechanism for generating this deletion. Deletion of exons 5 and 6 is predicted to lead to an inframe deletion which results in partial loss of the seven ankyrin repeats of the PLA2G6 protein.
Ankyrin repeats mediate protein-protein interactions and loss or disruption of this motif would be predicted to have a deleterious effect on normal iPLA 2 -VI function.
Conclusion
In conclusion, we describe the first reported use of MLPA in PLA2G6 analysis. Our data suggests that CNVs also have a role in the pathogenesis of PLAN. As part of a PLA2G6 diagnostic screening service, MLPA may contribute towards providing a definitive diagnosis in an affected individual. It may also help remove the need for unnecessary neurological investigation, improve the quality of genetic counselling and aid accurate prenatal diagnoses. It can provide greater understanding of disease genotype-phenotype correlation as well as insights into sequence-related chromosomal breakpoints, recombination hotspots and disease mechanisms. Our observations thus have implications for molecular diagnosis and highlight the importance of MLPA as a second-line diagnostic tool and adjunct to direct sequencing in PLA2G6 screening. 
